Related Experiment Video

Updated: Dec 10, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Breaking Barriers in HER2+ Cancers

Salvatore Siena1, Silvia Marsoni2, Andrea Sartore-Bianchi1

  • 1Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy.

Cancer Cell
|August 29, 2020
PubMed

Insights

Trastuzumab deruxtecan significantly improves outcomes for patients with HER2-positive metastatic gastroesophageal cancer. This novel immunoconjugate offers new hope where other HER2-targeted therapies have shown limited benefit.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Metastatic gastroesophageal carcinoma (GEA) with HER2-positive (HER2+) status has limited treatment options.
  • Trastuzumab is the only HER2-targeted therapy with demonstrated efficacy in HER2+ GEA.
  • There is a critical need for novel therapeutic strategies to improve patient survival and response rates.

Purpose of the Study:

  • To evaluate the efficacy and safety of the immunoconjugate trastuzumab deruxtecan in patients with HER2+ metastatic GEA.
  • To assess the impact of trastuzumab deruxtecan on response rates and overall survival.
  • To compare the benefits of trastuzumab deruxtecan against existing treatment paradigms.

Main Methods:

  • A clinical study involving patients diagnosed with HER2-positive metastatic gastroesophageal carcinoma.
  • Treatment administered included the immunoconjugate trastuzumab deruxtecan.
  • Key outcomes measured were objective response rate and overall survival.

Main Results:

  • Trastuzumab deruxtecan demonstrated unprecedented improvements in patient response.
  • Significant enhancements in overall survival were observed in the treatment group.
  • These findings represent a major advancement in the management of HER2+ GEA.

Conclusions:

  • Trastuzumab deruxtecan offers a highly effective treatment option for HER2-positive metastatic GEA.
  • The immunoconjugate provides substantial clinical benefit, surpassing previous HER2-targeted therapies.
  • This study highlights the potential of trastuzumab deruxtecan to change the standard of care for this patient population.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K